A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Omid Hamid, Henrik Schmidt, Aviram Nissan, Laura Ridolfi, Steinar Aamdal, Johan Hansson, Michele Guida, David M. Hyams, Henry Gómez, Lars Bastholt, Scott D. Chasalow, David Monty Berman · 2011
Read A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma by Omid Hamid, Henrik Schmidt, Aviram Nissan, Laura Ridolfi, Steinar Aamdal, Johan Hansson, Michele Guida, David M. Hyams, Henry Gómez, Lars Bastholt, Scott D. Chasalow, David Monty Berman (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/openalex-w2138134458.txt.
Description
Omid Hamid, Henrik Schmidt, Aviram Nissan, and colleagues published this trial in the Journal of Translational Medicine in 2011. They tested ipilimumab, an immune drug for advanced melanoma, and hunted for tumor signs that predict who benefits. The drug frees T cells to attack cancer by blocking a brake protein called CTLA-4.
Eighty-two patients with hard-to-treat melanoma received one of two dose levels. Tumor samples were taken before treatment and soon after the second dose. Response and safety matched earlier trials, and gene variants showed no link to benefit. Tumors starting with high levels of two immune markers responded better. So did tumors where immune cells flowed in more after treatment began.
Catalog record
| CREATOR | Omid Hamid, Henrik Schmidt, Aviram Nissan, Laura Ridolfi, Steinar Aamdal, Johan Hansson, Michele Guida, David M. Hyams, Henry Gómez, Lars Bastholt, Scott D. Chasalow, David Monty Berman |
|---|---|
| YEAR | 2011 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 74 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | OpenAlex / Journal of Translational Medicine |